Participants are randomly assigned to either the active drug or placebo and will take the tablets daily for roughly 18 months alongside their cancer treatment. Heart function is measured at the start and at the end of the study using CMR, a special type of MRI that visualizes the heart. The primary assessment is the change in LVEF, which indicates how well the left side of the heart pumps blood. Additional evaluations include GLS, a measure of how the heart muscle stretches during beats, and blood tests for NT-proBNP and the high‑sensitivity cardiac injury markers hs‑TnI and hs‑TnT.

The treatment is given as an intravenous infusion, which means it is delivered through a vein. The study looks at whether the new drug combination can help keep the cancer from coming back and whether it can remove all signs of invasive cancer in the breast and nearby lymph nodes before surgery. The course of the study includes treatment over a planned period, followed by surgery and later follow-up visits to monitor health over time.

Some medical terms used in the study include neoadjuvant, which means treatment given before surgery, and EFS, which means the length of time without a cancer-related event such as the cancer returning or worsening. The study also records side effects and overall health changes during follow-up.

Participants may receive elacestrant, which is a type of medication used to block the effects of hormones that help cancer grow. Some individuals might also be given ribociclib, a medication known as a CDK4/6 inhibitor that helps stop cancer cells from dividing. The treatments are administered as oral use tablets. Depending on the group assigned, some participants may receive these medications alone or in combination with other standard hormone therapies, and some may receive a placebo.

The study follows participants over a period of time to monitor how they respond to the different medication combinations. The process involves tracking long-term outcomes, such as overall survival, which is the length of time from the initial diagnosis until death, and disease-free survival, which measures the time during and after treatment that a person lives without any signs or symptoms of the cancer. The researchers will also look at how the treatments affect the quality of life and any side effects that may occur during the study period.

During the study, participants will take abemaciclib tablets for up to six months as part of their standard treatment after surgery. Blood samples will be collected at different times to measure the levels of the medication and its breakdown products in the body. The study team will also monitor participants for side effects, particularly diarrhea and low white blood cell counts, which is called neutropenia and can make it harder for the body to fight infections. The information gathered will help doctors better understand how the medication works in the body and how its levels relate to the occurrence of these side effects.

The study will also look at whether the amount of medication circulating freely in the blood, rather than being bound to proteins, affects how people respond to treatment and whether this relates to other health factors. By combining information about medication levels in the blood over time with information about when side effects occur, researchers aim to develop a mathematical model that could help predict which patients might experience more severe side effects. This information may help doctors adjust treatment doses in the future to reduce side effects while maintaining the benefits of the medication.

The study involves giving patients an injection of gadopiclenol before their scheduled MRI scan. This contrast agent helps make certain areas of the body more visible during the scan. The examination will take place before planned breast cancer surgery. The dose of gadopiclenol used in the study is 0.5 millimoles per milliliter, given as a single injection.

During the study, doctors will compare the detailed images from the MRI scan with the results from examining the breast tissue after surgery. They will look at various features of the cancer seen on the MRI images, such as size and appearance, and compare these with the actual characteristics of the tumor found during laboratory examination of the surgically removed tissue. This will help determine how accurate the contrast-enhanced MRI is in showing the details of breast cancer.

During the study, participants will receive either oxytocin nasal spray or a placebo nasal spray containing salt water. The treatment will be given through the nose for up to 5 days. Throughout the study period, participants will complete various questionnaires about their stress levels, emotional state, sleep quality, and thinking abilities. They will also perform some computer-based tasks to assess their cognitive function.

The study aims to understand if using oxytocin nasal spray can help reduce psychological distress that many people experience after breast cancer treatment. The research will measure changes in stress levels, anxiety, depression, and overall quality of life to determine if this treatment approach could be beneficial for breast cancer survivors.

The study examines whether adjusting tamoxifen doses (10 mg, 20 mg, or 40 mg daily) based on individual patient factors leads to better long-term use of the medication compared to the current standard treatment of 20 mg daily. Patients will be randomly assigned to either receive the standard fixed dose or a personalized dose. The treatment will continue for up to 5 years, during which patients will need to take tablets daily.

Throughout the study, doctors will monitor how well patients tolerate the medication and track various aspects of their health, including quality of life and any return of cancer. Blood samples will be collected to measure how the medication is working in the body. The study will also look at the density of breast tissue on mammograms and evaluate the overall effectiveness of the treatment.

The purpose of this study is to evaluate the safety and effectiveness of the combination of capivasertib and fulvestrant in patients whose cancer has progressed despite previous hormone-based treatments. Participants in the study will receive these medications and will be monitored to assess how long they can continue the treatment before needing to switch to another therapy. The study will also look at how this treatment affects the quality of life of the participants.

Throughout the study, participants will take the medications orally and will be regularly assessed by healthcare professionals. The study aims to provide insights into how well this combination of treatments works in managing advanced breast cancer and improving the time patients can stay on treatment. The trial will also explore the impact of the treatment on patients’ daily lives and overall well-being.

Participants in the study will receive the imaging agent 68Ga-ABY-025 through an injection, and then undergo a PET scan to visualize the HER2 expression in their cancer. After this, they will receive the treatment trastuzumab deruxtecan, which is given as an infusion. The study will monitor changes in the cancer and assess the treatment’s effectiveness over time. The goal is to understand if the initial imaging can help predict which patients will benefit most from the treatment.

This study is important because it could lead to better ways to tailor treatments for patients with HER2-positive metastatic breast cancer, potentially improving outcomes by identifying those who are most likely to benefit from specific therapies. The study will also look at how the treatment affects patients’ quality of life and overall survival. Participants will be followed for a period to gather comprehensive data on the treatment’s impact.

The trial is testing a combination of two treatments: pembrolizumab and olaparib. Pembrolizumab is a type of medicine called a PD-1 inhibitor, which helps the immune system recognize and attack cancer cells. Olaparib is a PARP inhibitor, which helps prevent cancer cells from repairing themselves, leading to their death. The purpose of the study is to see how effective this combination is in treating the cancer. Participants will receive these treatments over a period of 27 weeks, and their response to the treatment will be monitored.

Throughout the study, researchers will observe how well the cancer responds to the treatment, how long the response lasts, and how long patients live without the cancer getting worse. They will also monitor any side effects or serious health issues that may occur. This information will help determine if the combination of pembrolizumab and olaparib is a beneficial treatment option for patients with this specific type of breast cancer.

The study compares two treatment approaches: patients will receive either sacituzumab govitecan or a standard treatment chosen by their doctor from several options including carboplatin, cisplatin, or capecitabine. The purpose is to determine if sacituzumab govitecan is more effective at preventing the cancer from returning compared to standard treatments.

Treatment will continue for up to 24 months. The medications are given either through an intravenous infusion directly into the bloodstream or as tablets taken by mouth, depending on which treatment the patient receives. All patients must have completed their previous treatments, including surgery and radiation therapy, before starting the study medication.

The purpose of the study is to measure the levels of these drugs in the body and to see how they relate to side effects and treatment outcomes. This information could help doctors adjust doses for future patients to avoid giving too much or too little of the medication. The study will involve monitoring patients who are receiving these drugs as part of their breast cancer treatment. The researchers will look for patterns between the amount of drug exposure and various health effects, such as blood health, liver function, heart health, and overall quality of life.

Throughout the study, participants will receive their usual breast cancer treatments, and the researchers will collect information on how the drugs affect them. The study will also explore whether certain genetic factors might influence how patients process these drugs, which could help identify those at risk of receiving too much or too little medication. The ultimate goal is to improve treatment by tailoring drug doses to each patient’s needs, potentially leading to better outcomes and fewer side effects.

The purpose of the study is to evaluate the benefit of adding chemotherapy to the treatment plan for elderly patients who have a high risk of cancer returning, as determined by a specific test called the Genomic Grade (GG). Participants in the study will receive treatment over a period of up to 12 months. The study will follow participants for four years to assess their overall survival, which means the length of time they live after starting the treatment. Other aspects being evaluated include the quality of life and any side effects experienced during the treatment.

This trial is part of a larger effort by the French UNICANCER Geriatric Oncology Group and Breast Group to improve treatment options for older women with this type of breast cancer. The study aims to provide valuable information on how effective the combination of chemotherapy and hormone therapy is in improving survival rates and quality of life for these patients. Participants will be closely monitored throughout the study to ensure their safety and well-being.

Participants in the study will take part in a treatment period that can last up to 24 months. During this time, they will receive either the combination of endocrine therapy and ribociclib or chemotherapy. The study aims to observe the participants over a period of time to see how well the treatments work in preventing the cancer from coming back and to monitor the overall health and quality of life of the participants.

The study will also look at how well participants adhere to their treatment plans, which means how consistently they take their medication as prescribed. Additionally, researchers will collect information on the participants’ response to treatment, including any changes in the size of the tumor and the rate of breast-conserving surgeries. The ultimate goal is to find the most effective treatment option for patients with HR-positive/HER2-negative early breast cancer, improving their chances of living without the disease returning.

Participants in the study will receive one of several possible treatments, which include medications such as Palbociclib, Capecitabine, Niraparib, Doxorubicin Hydrochloride, Topotecan, Paclitaxel, Sacituzumab Govitecan, Fulvestrant, Carboplatin, Docetaxel, Vinorelbine, Olaparib, Bevacizumab, Cyclophosphamide, and Etoposide. Some patients may receive a placebo, which is a substance with no active medication. The study will last for a maximum of 24 months, during which the effectiveness of the treatments will be monitored.

The main goal of the study is to see if the zAvatar-test can better predict which treatments will work best for patients, helping to improve their progression-free survival, which means the length of time during and after treatment that a patient lives with the disease without it getting worse. The study will also look at other outcomes, such as the overall survival of patients and their response to the treatments. This research could lead to more personalized and effective treatment options for patients with these types of cancer.

Participants in the study will take these medications orally for a period of up to two weeks before their scheduled breast surgery. The study aims to observe any changes in the cancer cells by comparing samples taken before and after the treatment. This will help researchers understand if the antibiotics can slow down or stop the cancer cells from multiplying.

The trial includes patients with different types of early-stage breast cancer, specifically those in stages I to III. By examining the effects of these antibiotics, the study hopes to find new ways to manage breast cancer before surgery. The results could provide valuable insights into how these medications might be used to improve treatment outcomes for breast cancer patients in the future.

The purpose of the study is to compare the effectiveness of different treatment combinations in improving the 5-year event-free survival of patients. Event-free survival refers to the length of time after treatment during which a patient remains free from certain complications or events that the study is measuring. Participants will receive treatment over a period of time, and their health will be monitored to assess the outcomes. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatments.

Throughout the study, participants will undergo regular health assessments to monitor their response to the treatment. The study aims to provide valuable information on the best treatment strategies for patients with HER2-positive breast cancer, potentially leading to improved outcomes and survival rates. The trial is expected to conclude by the end of 2026, with results helping to guide future treatment approaches for this type of cancer.

Participants in the study will receive either the combination of Capivasertib and Fulvestrant or a placebo with Fulvestrant. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The trial will monitor the participants over time to assess the progression of the disease and any side effects that may occur. The study will also look at specific genetic changes, such as PIK3CA mutations, to see if they affect how well the treatment works.

The trial aims to provide valuable information on the safety and effectiveness of Capivasertib and Fulvestrant in treating this type of breast cancer. It will also gather data on overall survival rates, response to treatment, and quality of life for participants. The study is expected to continue until 2025, allowing researchers to collect comprehensive data on the long-term effects of the treatment. Participants will be closely monitored throughout the study to ensure their safety and well-being.

The purpose of the study is to see if the combination of sacituzumab govitecan and pembrolizumab is more effective than sacituzumab govitecan alone. Participants in the study will receive one of these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will last for up to 18 months, during which time participants will receive regular treatments and follow-up care to monitor their health and the effectiveness of the treatment.

Throughout the study, doctors will check for the absence of cancer in the breast and lymph nodes, which is known as a complete response. They will also track the participants’ health over three years to see if the cancer stays away. The study aims to improve treatment options for people with this type of breast cancer and to increase the chances of long-term health and recovery.

The purpose of the study is to evaluate how well this fertility preservation method works in terms of the number of mature eggs that can be successfully frozen. Participants will undergo a controlled ovarian stimulation process, which is a way to encourage the ovaries to produce multiple eggs. The study will monitor the quality and number of eggs and embryos that can be preserved. It will also assess the safety of the procedures and any potential impact on the timing of cancer treatment.

Throughout the study, the participants’ ovarian reserve, which is the capacity of the ovaries to produce eggs, will be evaluated. This is done by measuring levels of a hormone called AMH and counting the number of small follicles in the ovaries. The study will also look at the effects of chemotherapy on fertility, such as the risk of chemotherapy-induced menopause. The trial will follow participants for up to ten years to track pregnancy outcomes and overall health. This research aims to provide valuable insights into preserving fertility for young women undergoing cancer treatment.

The purpose of the study is to evaluate how well CEM with *Iomeprol* can identify breast lesions that are classified as BIRADS 4 or 5. BIRADS is a system used by doctors to categorize the level of suspicion for cancer in breast imaging findings, with 4 and 5 indicating a higher likelihood of cancer. Participants in the study will receive a dose of the contrast agent based on their body weight, specifically 1 mL per kilogram. The study will involve initial mammography and ultrasound examinations, followed by additional imaging at 6 and 12 months after the CEM procedure to monitor any changes.

Throughout the study, various health parameters will be monitored, including kidney function tests such as creatinine and eGFR, as well as other blood components like serum albumin, sodium, and potassium. These tests help ensure the safety of the participants while assessing the effectiveness of the CEM technique in detecting breast cancer. The study aims to provide valuable insights into the potential benefits of using *Iomeprol* in enhancing mammography for better cancer detection.

Participants in the study will receive these medications through infusions or injections over a period of time. The study will monitor how the cancer responds to these treatments and assess the long-term outcomes for the patients. The goal is to determine the effectiveness of the treatment in reducing the size of the tumor and improving the chances of successful surgery. The study will also look at the safety of the treatments and their impact on the quality of life of the participants.

Throughout the study, various aspects such as the clinical and radiological response of the cancer, the characteristics of the tumors, and the survival rates of the patients will be evaluated. The study will also consider the frequency of breast-conserving surgeries and the overall safety of the treatment regimen. This research is part of a larger effort to improve treatment strategies for patients with HER2-positive breast cancer.

The purpose of this study is to determine if a combination of Giredestrant and Triptorelin is more effective in reducing cancer cell growth compared to a combination of Anastrozole and Triptorelin. Additionally, the study will assess if Giredestrant alone can provide similar benefits as when it is combined with Triptorelin. Participants will receive these treatments over a period of four weeks. The study will involve taking medication either orally or through an injection, depending on the specific treatment being tested.

Throughout the study, participants will undergo regular monitoring to assess the effects of the treatments on their cancer. This will include taking samples from the tumor before and after the treatment period to evaluate changes in cancer cell activity. The study aims to provide valuable insights into the effectiveness of these hormone therapies in managing ER-positive/HER2-negative early breast cancer in premenopausal women.

Participants in the study will be randomly assigned to one of two groups. One group will receive the combination of abemaciclib and standard hormone therapy, while the other group will receive only the standard hormone therapy. The study will be conducted in an open-label manner, meaning that both the participants and the researchers will know which treatment each participant is receiving. The treatment period will last up to 24 months, during which participants will take the medication orally in the form of film-coated tablets. Throughout the study, participants will be monitored regularly to assess their health and the effectiveness of the treatment.

The main goal of the study is to determine if the combination of abemaciclib and standard hormone therapy can improve the time participants remain free from invasive breast cancer compared to those receiving only the standard hormone therapy. Additionally, the study will look at other outcomes, such as overall survival and quality of life, to provide a comprehensive understanding of the treatment’s impact. Participants will be followed for several years to gather long-term data on the effectiveness and safety of the treatment.

The purpose of the study is to estimate the survival rates of patients, focusing on how long they live without the cancer getting worse and their overall survival at 12 months. Participants will receive treatment for up to 48 months, during which they will take Ribociclib and one of the other medications mentioned. Some participants may receive a placebo instead of one of the medications to help compare the effects. The study will monitor the participants’ health and any side effects they experience during this period.

Throughout the study, participants will have regular check-ups and tests to track their progress and the effectiveness of the treatment. The study will also assess the quality of life of the participants using a questionnaire called FACT-G/FACT-B, which is designed to measure health-related quality of life in cancer patients. The ultimate goal is to gather comprehensive data on how Ribociclib and the other medications work together in treating advanced breast cancer, providing valuable insights for future treatments.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

The purpose of the study is to see how well these treatments work in helping patients achieve a complete response, meaning no signs of cancer, after 12 or 18 weeks of treatment. The study will also look at whether patients treated with trastuzumab deruxtecan have a high chance of being free from distant cancer spread for three years. Patients will be monitored throughout the study to see how their cancer responds to the treatment and to check their overall health and quality of life.

Participants in the study will receive their assigned treatment and will have regular check-ups to monitor their progress. The study aims to provide valuable information on the effectiveness of these treatments in managing HER2-positive early breast cancer and to help guide future treatment options for patients with this condition.